FLDcure (639314)

  https://cordis.europa.eu/project/id/639314

  Horizon 2020 (2014-2020)

  A potent Micro-RNA therapeutic for nonalcoholic fatty liver disease (NAFLD)

  ERC Proof of Concept Grant (ERC-PoC-2014)

  liver cancer  ·  hepatology

  2015-01-01 Start Date (YY-MM-DD)

  2016-06-30 End Date (YY-MM-DD)

  € 149,800 Total Cost

  Description

Fatty Liver disease (FLD) is a widespread disease which can often progress to Nonalcoholic steatohepatitis, cirrhosis and liver cancer. At present FLD disease affects a huge perportion of the population and prompt treatment will be of major health benefits to the general population. We have developed a specific therapeutic targeting a microRNA we and others have shown to be involved in the pathogenesis of FLD. This therapeutic agent can dramatically reduce FLD in a mouse model. We would like to extend the pre-clinical studies in order to encourage interest of a pharmaceutical company who will license the technology and pursue clinical trials.

  Complicit Organisations

1 Israeli organisation participates in FLDcure.